16. ANALYSIS OF TREATMENT COSTS ACCORDING TO TREATMENT OUTCOMES OF INVASIVE CANDIDA INFECTIONS AT CHILDREN'S HOSPITAL 2
Main Article Content
Abstract
Objective: To analyze treatment costs according to patient characteristics, drug utilization characteristics, and factors related to the treatment costs of pediatric patients with invasive Candida infections at Children's Hospital 2.
Subjects and methods: A descriptive cross-sectional, retrospective study on 273 medical records of pediatric patients with invasive Candida infections during the period 2022–2023.
Results: The median total treatment cost for pediatric patients with invasive Candida infections was 95,734,470 VND (range: 45,743,101 – 160,596,329 VND). The majority of treatment costs were covered by health insurance, accounting for 95.73%. Medication costs represented 34.59% of the total treatment cost. Caspofungin was the antifungal agent with the highest median cost at 51,004,800 VND (range: 31,911,040 – 80,085,950 VND). Candida parapsilosis was the most frequently isolated species and also contributed the highest proportion of treatment costs (>30% of the total treatment cost). Linear regression analysis suggested that factors such as changes in antifungal therapy and length of hospital stay were associated with increased treatment costs.
Conclusion: The study results provided preliminary data on the treatment costs of invasive Candida infections in pediatric patients, highlighting the need for appropriate treatment strategies and early interventions to reduce the financial burden on the public healthcare system in Vietnam.
Article Details
Keywords
treatment cost, invasive Candida infection, pediatric patients.
References
[2] Ha YE, Peck KR, Joo EJ, et al. (2012). Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother;56(7):3950-6. doi:10.1128/aac.06258-11
[3] Moran C, Grussemeyer CA, Spalding JR, Benjamin Jr DK, Reed SD (2009).. Candida albicans and non-albicans bloodstream infections in adult and pediatric patients: comparison of mortality and costs. The Pediatric infectious disease journal;28(5):433-435.
[4] Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. (2005). The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity Analysis. Clinical Infectious Diseases;41(9):1232-1239. doi:10.1086/496922
[5] Slavin M, Fastenau J, Sukarom I, Mavros P, Crowley S, Gerth WC. (2024). Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. International journal of infectious diseases;8(2):111-120.
[6] Gebretekle GB, Fentie AM, Gebremariam GT, et al. (2022). Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia. BMC Health Services Research;22(1):1302.
[7] Gagne JJ, Breitbart R, Maio V, et al. (2006).Costs associated with candidemia in a hospital setting. P AND T;31(10):586.
[8] Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. (2019).Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Oxford University Press US:S79-S94.